We foster and enhance partnerships with industry, maximising opportunities to leverage and translate knowledge to deliver economic and social benefit.
Researchers at the University of Adelaide have been awarded $1.35 million in funding to accelerate development of a world-first vaccine for the Zika virus. Zika – a mosquito-transmitted ‘flavivirus’ causes microcephaly and other severe birth defects in infants born to infected mothers.
Through the establishment of the Australian Advanced Materials Manufacturing Facility, and partnerships with global leaders, we have driven 3D metal additive manufacturing capability in SA.
Our spin-outs and start-ups
We work with researchers at the University of Adelaide to license or assign their technologies to start-up or spin-out companies. Spin-outs are companies launched by the University of Adelaide with University intellectual property (IP); and start-ups are companies launched by others, based partly or entirely on our IP. Here are a selection of the companies we are working with.
Amaero manufactures components for a range of global companies and SME’s in North America, Europe, Asia and Australia. Amaero offers great depth of technical knowledge and broad capability and has experience in dealing with sensitive projects including ITAR and classified defence projects.
Bygen have developed a process that allows a wide-variety of agricultural wastes to be used in an integrated approach for the generation of clean energy and the value-added products "biochar" and “activated carbon”, with minimal processing requirements.
Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. CAR-T therapy is a revolutionary new treatment option that uses a patient’s immune system to fight their cancer.
Fertilis technology involves each embryo growing inside its own patented micro-3D printed pod. The pod protects the embryo and enables automated subtle changes to the nutritive composition of the formulated solutions that bathes the embryo, providing the most optimised growth environment ever developed.
Sparc Technologies Limited (ASX:SPN) is a South Australian based company that is focusing on the development of innovative technology solutions using the unique properties of graphene.